Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
03
2019
accepted:
07
07
2019
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
27
2
2020
Statut:
epublish
Résumé
The complement system is involved in pathogenesis of cardiovascular disease, and might play a role in accelerated atherogenesis in spondylarthropathies (SpA). Hence, we examined complement activation in SpA, and its relationship to antirheumatic treatment, inflammatory and cardiovascular markers. From PSARA, a prospective observational study, we examined 51 SpA patients (31 psoriatic arthritis (PsA), and 20 ankylosing spondylitis (AS)), starting tumor necrosis factor (TNF) inhibitor alone (n = 25), combined with methotrexate (MTX) (n = 10), or MTX monotherapy (n = 16). Complement activation was determined by the soluble terminal complement complex (sC5b-9), inflammation by erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and endothelial function by finger plethysmography (Endopat) at baseline, after 6 weeks and 6 months of treatment. SpA patients had sC5b-9 levels at (PsA) or above (AS) the upper limit of the estimated reference range. Median sC5b-9 levels decreased significantly from baseline to 6 weeks, with no significant difference between the AS and PsA group. Notably, a significant reduction in sC5b-9 was observed after administration of TNF inhibitor ± MTX, whereas no significant changes were observed in patients treated with MTX alone. Between 6 weeks and 6 months, sC5b-9 remained stable across all subgroups. Reduction in sC5b-9 was independently related to decreased ESR and CRP, and to increased high density cholesterol and total cholesterol. Reduction in sC5b-9 from baseline to 6 weeks was associated with improved EF in age and gender adjusted analyses. TNF-inhibition, but not MTX monotherapy, led to rapid and sustained reduction of complement activation in SpA. Thus, the observed decrease in cardiovascular morbidity in patients treated with TNF-inhibitors might be partly due to its beneficial effect on complement. Clinical Trials (NCT00902005), retrospectively registered on the 14th of May 2009.
Sections du résumé
BACKGROUND
The complement system is involved in pathogenesis of cardiovascular disease, and might play a role in accelerated atherogenesis in spondylarthropathies (SpA). Hence, we examined complement activation in SpA, and its relationship to antirheumatic treatment, inflammatory and cardiovascular markers.
METHODS
From PSARA, a prospective observational study, we examined 51 SpA patients (31 psoriatic arthritis (PsA), and 20 ankylosing spondylitis (AS)), starting tumor necrosis factor (TNF) inhibitor alone (n = 25), combined with methotrexate (MTX) (n = 10), or MTX monotherapy (n = 16). Complement activation was determined by the soluble terminal complement complex (sC5b-9), inflammation by erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and endothelial function by finger plethysmography (Endopat) at baseline, after 6 weeks and 6 months of treatment.
RESULTS
SpA patients had sC5b-9 levels at (PsA) or above (AS) the upper limit of the estimated reference range. Median sC5b-9 levels decreased significantly from baseline to 6 weeks, with no significant difference between the AS and PsA group. Notably, a significant reduction in sC5b-9 was observed after administration of TNF inhibitor ± MTX, whereas no significant changes were observed in patients treated with MTX alone. Between 6 weeks and 6 months, sC5b-9 remained stable across all subgroups. Reduction in sC5b-9 was independently related to decreased ESR and CRP, and to increased high density cholesterol and total cholesterol. Reduction in sC5b-9 from baseline to 6 weeks was associated with improved EF in age and gender adjusted analyses.
CONCLUSION
TNF-inhibition, but not MTX monotherapy, led to rapid and sustained reduction of complement activation in SpA. Thus, the observed decrease in cardiovascular morbidity in patients treated with TNF-inhibitors might be partly due to its beneficial effect on complement.
TRIAL REGISTRATION
Clinical Trials (NCT00902005), retrospectively registered on the 14th of May 2009.
Identifiants
pubmed: 31335881
doi: 10.1371/journal.pone.0220079
pii: PONE-D-19-08393
pmc: PMC6650069
doi:
Substances chimiques
Complement Membrane Attack Complex
0
SC5b-9 protein complex
0
Tumor Necrosis Factor Inhibitors
0
Methotrexate
YL5FZ2Y5U1
Banques de données
ClinicalTrials.gov
['NCT00902005']
Types de publication
Controlled Clinical Trial
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0220079Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
NeuroRx. 2004 Jul;1(3):341-7
pubmed: 15717036
Semin Arthritis Rheum. 2004 Dec;34(3):585-92
pubmed: 15609262
Scientifica (Cairo). 2012;2012:402783
pubmed: 24278688
Thromb Res. 2008;122(2):221-8
pubmed: 18166221
Immunology. 2016 Feb;147(2):152-64
pubmed: 26572245
J Am Coll Cardiol. 2004 Dec 7;44(11):2137-41
pubmed: 15582310
J Autoimmun. 2010 May;34(3):J276-86
pubmed: 20005073
J Biol Chem. 1993 Feb 15;268(5):3632-8
pubmed: 8429039
Ann Rheum Dis. 2005 Jul;64(7):1003-8
pubmed: 15958758
Mol Immunol. 2013 Dec 15;56(3):232-9
pubmed: 23787367
Clin Exp Immunol. 1991 May;84(2):250-5
pubmed: 2025952
J Immunol. 2013 Apr 15;190(8):3831-8
pubmed: 23564577
J Clin Invest. 1986 Nov;78(5):1349-54
pubmed: 2429991
Curr Opin Rheumatol. 2007 Jul;19(4):358-62
pubmed: 17551366
J Hypertens. 2005 Jan;23(1):7-17
pubmed: 15643116
Arthritis Rheum. 2009 May;60(5):1324-30
pubmed: 19404933
Atherosclerosis. 2017 Apr;259:104-113
pubmed: 28242049
Nat Rev Rheumatol. 2012 Aug;8(8):458-68
pubmed: 22664835
Nat Rev Rheumatol. 2015 Dec;11(12):693-704
pubmed: 26282082
Clin Exp Rheumatol. 2012 Jan-Feb;30(1):23-30
pubmed: 22260811
Handb Exp Pharmacol. 2015;224:455-82
pubmed: 25522998
Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S76-80
pubmed: 12463453
Mol Immunol. 2010 Feb;47(5):1098-105
pubmed: 19959238
Int J Cardiol. 2014 Jun 15;174(2):400-3
pubmed: 24794956
Arthritis Rheum. 2002 Apr;46(4):934-45
pubmed: 11953970
Clin Exp Med. 2002 May;2(1):33-8
pubmed: 12049187
Arthritis Rheum. 1991 Dec;34(12):1531-7
pubmed: 1747138
Autoimmun Rev. 2011 Oct;10(12):773-8
pubmed: 21684355
Nature. 2002 Dec 19-26;420(6917):868-74
pubmed: 12490960
PLoS One. 2017 Feb 22;12(2):e0169830
pubmed: 28225768
Mol Immunol. 2014 Oct;61(2):135-48
pubmed: 25017306
Clin Chem. 2009 Feb;55(2):209-15
pubmed: 19095723
Scand J Gastroenterol. 2003 Oct;38(10):1050-4
pubmed: 14621279
PLoS One. 2016 Sep 08;11(9):e0162316
pubmed: 27606615
Mol Immunol. 2015 Oct;67(2 Pt A):117-30
pubmed: 25697848
Curr Allergy Asthma Rep. 2015 Jan;15(1):489
pubmed: 25447326
Circulation. 2012 Aug 7;126(6):753-67
pubmed: 22869857
J Clin Invest. 1985 Mar;75(3):1000-7
pubmed: 3156879
Am Heart J. 2012 Nov;164(5):786-92
pubmed: 23137511
Clin Exp Rheumatol. 2003 Mar-Apr;21(2):225-8
pubmed: 12747280
Ann Rheum Dis. 2010 Feb;69(2):325-31
pubmed: 19773290
Int Heart J. 2015;56(2):125-34
pubmed: 25740586
Am J Physiol. 1991 Apr;260(4 Pt 1):L254-9
pubmed: 1902064